Document Detail


Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.
MedLine Citation:
PMID:  15625613     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inhalation device and inhalation technique influence the deposition of drug in the lung. This study evaluated the efficacy of salbutamol as a bronchoprotective agent administered via Diskus, Turbuhaler, pMDI or pMDI + Volumatic against methacholine-induced bronchoconstriction. METHODS: Twenty stable asthmatics participated in this open randomised comparison of the protective effects of 200 microg salbutamol, administered via the various inhalation devices on methacholine-induced airway obstruction, with respect to pulmonary function and dyspnoea sensation. The inhalation technique was controlled by measuring the peak inspiratory flow (and actuation time, in the case of pMDI and Volumatic) through the device, during inhalation. RESULTS: Inhalation of salbutamol increased the provocative dose of methacholine by 1.2 doubling doses (dd) for pMDI, 1.9 dd for Diskus, 2.3 dd for Turbuhaler and 2.5 dd for Volumatic. Salbutamol via pMDI provided less protection from methacholine-induced airway obstruction than did salbutamol administered via Diskus, Turbuhaler or Volumatic (P<0.05). The inadequate pMDI use of 70% of our patients might contribute to a lower deposition of drug in the central airways, resulting in the lower protective effect. However, the PC20_FEV1 of the adequate- and inadequate pMDI users showed no significant difference. CONCLUSION: Salbutamol administered via pMDI gave less protection from methacholine-induced bronchoconstriction than did salbutamol via Diskus, Turbuhaler or Volumatic. This study suggests that the pMDI may be less suitable for protecting a patient against bronchoconstriction due to airway hyperresponsiveness.
Authors:
Mariëlle E A C Broeders; Johan Molema; Wim C J Hop; Hans Th M Folgering
Related Documents :
20659403 - Comparison of risk of neurovascular and cardiovascular side effects between tiotropium ...
2947783 - Site of bronchodilatation with inhaled ipratropium bromide and fenoterol in normal subj...
25445833 - Analyzing the impact of different excipients on drug release behavior in hot-melt extru...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2004-12-30
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  60     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-03-02     Completed Date:  2005-06-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  837-41     Citation Subset:  IM    
Affiliation:
Department of Pulmonary Diseases Dekkerswald, University of Nijmegen, P.O. Box 9001, 6560, GB Groesbeek, The Netherlands. m.broeders@zonnet.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Albuterol / administration & dosage*,  therapeutic use
Asthma / drug therapy
Bronchial Provocation Tests
Bronchoconstrictor Agents / diagnostic use*
Bronchodilator Agents / administration & dosage*,  therapeutic use
Female
Humans
Male
Metered Dose Inhalers
Methacholine Chloride / diagnostic use*
Middle Aged
Nebulizers and Vaporizers*
Chemical
Reg. No./Substance:
0/Bronchoconstrictor Agents; 0/Bronchodilator Agents; 18559-94-9/Albuterol; 62-51-1/Methacholine Chloride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention of retrograde calculus migration with the Stone Cone.
Next Document:  Elevated levels of serum type I collagen C-telopeptide in patients with rapidly destructive osteoart...